Summary: The Centers for Medicare & Medicaid Services modified its verteporfin coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.
Verteporfin billing has always required precise documentation and tight medical necessity criteria. This CMS update to its verteporfin coverage policy changes the rules your claims will be adjudicated against starting May 15, 2026. The specific policy code is listed as N/A in the CMS system, but the clinical and billing implications are real. This post does not list specific codes provided by the payer document — the source policy does not include a code list — but we cover what's known and what your team should do now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Verteporfin |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Ophthalmology, retina specialists, outpatient facility billing |
| Key Action | Audit verteporfin claims and documentation before May 15, 2026, and confirm your medical necessity criteria align with the updated policy |
CMS Verteporfin Coverage Criteria and Medical Necessity Requirements 2026
Verteporfin — sold under the brand name Visudyne — is a photosensitizing agent used in photodynamic therapy (PDT) for certain retinal conditions. CMS has covered it for specific indications for years. This modification signals that CMS is tightening, clarifying, or restructuring how it evaluates those indications.
The CMS verteporfin coverage policy governs whether a claim passes or gets denied at the medical necessity level. That means your documentation has to match the policy's criteria line for line. If it doesn't, you're looking at a claim denial before you ever get to a remittance.
Because the source policy document does not provide the full updated criteria text, your first action is to pull the current policy directly from the CMS source at app.payerpolicy.org/p/cms/350-v2 and compare it to what your practice currently uses to support verteporfin claims. Do not assume your existing documentation templates still satisfy the updated requirements.
What we know about verteporfin coverage under Medicare historically:
| # | Covered Indication |
|---|---|
| 1 | Subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) — covered when predominantly classic CNV is present on fluorescein angiography |
| 2 | CNV secondary to pathologic myopia — covered under defined clinical conditions |
| 3 | Occult CNV without classic component — historically a contested area; coverage has been conditional |
Any modification to these long-standing criteria changes your medical necessity threshold. If CMS has narrowed indications, claims that passed before May 15, 2026 may not pass after. If CMS has expanded criteria, you may have claims you were under-billing that now qualify.
Prior authorization is not universally required for verteporfin under Medicare, but your Medicare Administrative Contractor (MAC) may have local coverage determination (LCD) guidance that layers on top of this national policy. Check with your MAC before the effective date. This is especially important if your practice operates in a region where the MAC has historically been more restrictive than CMS's national policy.
Reimbursement for verteporfin PDT is tied directly to the specificity of your diagnosis documentation. A vague clinical note will not survive a post-payment audit, let alone a pre-payment review.
CMS Verteporfin Exclusions and Non-Covered Indications
Historically, CMS has not covered verteporfin photodynamic therapy for several indications. While the updated policy document does not enumerate a revised exclusion list in the data available, the following have been non-covered or experimental under prior CMS policy:
| # | Excluded Procedure |
|---|---|
| 1 | Minimally classic or occult-only CNV from AMD — has been covered in some circumstances but denied in others based on lesion composition |
| 2 | CNV from causes other than AMD or pathologic myopia — generally not covered under national policy, though MACs may have LCDs addressing specific etiologies |
| 3 | Repeat PDT beyond established treatment intervals — claims for verteporfin PDT administered more frequently than CMS guidelines allow are at high risk for denial |
| 4 | Off-label uses — any indication not supported by the national coverage policy or a supporting LCD is not covered under Medicare |
If you bill for verteporfin in cases that fall outside the clearly covered indications, you need a current ABN (Advance Beneficiary Notice of Noncoverage) on file. A missing ABN in a non-covered scenario means you eat the cost.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Subfoveal CNV, predominantly classic, AMD | Covered | See code section below | Fluorescein angiography documentation required |
| Subfoveal CNV, pathologic myopia | Covered | See code section below | Clinical documentation must confirm pathologic myopia diagnosis |
| Occult CNV without classic component | Conditional / Variable | See code section below | MAC LCD may govern; verify with your MAC before billing |
| CNV from other etiologies (non-AMD, non-myopia) | Not Covered (National) | N/A | MAC LCD may provide limited exceptions |
| Repeat PDT beyond standard intervals | Not Covered | N/A | Medical record must justify repeat treatment; high denial risk |
| Off-label verteporfin use | Not Covered | N/A | ABN required; do not bill without patient financial agreement |
Note: The source policy does not provide a revised indication list in the available data. These indications reflect established CMS coverage history. Verify against the updated policy document before May 15, 2026.
CMS Verteporfin Billing Guidelines and Action Items 2026
This is where the rubber meets the road. Here's what your billing team needs to do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the updated policy and read it. Go to app.payerpolicy.org/p/cms/350-v2 and get the actual policy language. Do not rely on this post alone — use it as a starting point, then verify against the source. |
| 2 | Audit your verteporfin claims from the past 12 months. Look at the indications you've been billing, the diagnosis codes attached, and whether your documentation explicitly supports medical necessity under the criteria. If the new policy tightened criteria, claims filed after May 15, 2026 that match your old documentation pattern will fail. |
| 3 | Update your clinical documentation templates. Work with your ophthalmologists or retina specialists to make sure every verteporfin PDT note captures fluorescein angiography findings, lesion composition (classic vs. occult), lesion size, and prior treatment history. These are the fields that drive medical necessity determinations. |
| 4 | Check your MAC's LCD for verteporfin. The national CMS policy sets the floor. Your MAC may have a local coverage determination that adds criteria. Contact your MAC or pull their LCD directly. If your MAC has not issued an updated LCD aligned with this modified policy, watch for one — LCDs often follow NCD modifications. |
| 5 | Confirm your prior authorization workflow. While Medicare typically does not require prior authorization for verteporfin PDT, Medicare Advantage plans do — and many use CMS's national coverage policy as their baseline. If your verteporfin billing includes Medicare Advantage patients, verify each plan's prior auth requirements separately. A CMS policy change often triggers MA plan updates. |
| 6 | Review your ABN process for non-covered indications. If any of your verteporfin cases fall into gray-zone or non-covered territory, make sure ABNs are properly executed before the service date. This is not optional — it's the difference between a written-off claim and a collectible patient balance. |
| 7 | Brief your coding team on the effective date. May 15, 2026 is the hard line. Claims for dates of service on or after that date get adjudicated under the new rules. Make sure your coders and billers know this date and flag any verteporfin claims that straddle the transition. |
If you're uncertain how the modified policy applies to your specific patient mix or practice specialty, talk to your compliance officer or a billing consultant before May 15, 2026. The financial exposure on a high-volume retina practice can be significant if claims suddenly start denying at the indications level.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Verteporfin Under CMS Policy
The source policy document for this CMS verteporfin update does not provide a specific list of CPT, HCPCS, or ICD-10 codes. This post does not invent or guess codes.
That said, verteporfin billing guidelines have historically involved a defined set of codes that your billing team should verify against the updated policy. Work directly with the CMS policy document and your MAC to confirm which codes are listed as covered, not covered, or subject to additional criteria under the modified policy effective May 15, 2026.
What to Check in the Source Policy
When you pull the updated policy, look specifically for:
- HCPCS J-codes — verteporfin (Visudyne) is a drug administered in a clinical setting and billed separately from the photodynamic therapy procedure itself
- CPT procedure codes for ophthalmic PDT
- ICD-10-CM diagnosis codes specifying CNV etiology and laterality — these are the codes that determine whether a claim clears medical necessity review
Your charge capture for verteporfin billing should include both the drug administration code and the procedure code. Missing either one creates a claim that will not pay correctly, regardless of medical necessity documentation.
A Note on Drug Billing
Verteporfin is a separately billable drug under Medicare Part B when administered in a physician office or outpatient setting. Reimbursement is based on ASP (Average Sales Price) methodology. If CMS has updated the coverage policy, check whether the drug's coverage determination has also been revised — occasionally a policy modification affects both the procedure coverage and the drug's billable status.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.